GESS-AEEM consensus on testosterone therapy in women: a clinical implementation framework
This study aims to provide a Spanish clinical implementation consensus on systemic testosterone therapy in women, translating international evidence and guidance into an operational framework for Spain and comparable European settings. A multidisciplinary panel of 13 experts reviewed evidence identified through PubMed/MEDLINE, Embase and the Cochrane Library from January 2000 to April 2026. Sources were characterized by study design, directness, applicability and key limitations. Draft statements were refined through a two-round modified Delphi process, with agreement predefined as ≥80%. A revised special-populations statement underwent focused post-review confirmatory voting. No formal Grading of Recommendations Assessment, Development, and Evaluation (GRADE) assessment was performed. Physiological-dose transdermal testosterone may be considered for postmenopausal women with hypoactive sexual desire disorder after comprehensive biopsychosocial assessment. Serum testosterone should not be used diagnostically but supports safe prescribing and detection of supraphysiological exposure. The consensus addresses off-label prescribing, assay continuity, monitoring, discontinuation, safety communication and special populations. Non-transdermal formulations, supraphysiological dosing and use for non-sexual indications are not supported. This article does not propose a new therapeutic indication or supersede existing guidance. The article provides a contextualized implementation framework to support consistent and safe clinical practice. Testosterone therapy is sometimes prescribed to women after menopause to improve sexual desire. However, there is ongoing debate about when it should be used, how it should be prescribed and whether it is safe in the long term. In recent years, interest in testosterone has increased, including its use for symptoms such as low mood, fatigue or general well-being, despite limited scientific evidence supporting these indications. This consensus document, developed by the Sexual Health Section of the Spanish Menopause Association (GESS-AEEM), reviews the available scientific evidence and provides practical clinical guidance for clinicians. The strongest clinical evidence supports testosterone therapy for postmenopausal women with a well-defined condition called hypoactive sexual desire disorder, after a thorough clinical assessment that includes biological, psychological and relational factors. Blood testosterone levels should not be used to diagnose this condition but can help ensure safe treatment. Transdermal formulations (applied to the skin) are preferred. Other forms, such as injections or compounded products, are not recommended. Current trials have not identified major short-term safety signals in carefully selected patients, but long-term safety remains uncertain. Testosterone should not be used for other purposes, such as improving mood, cognition or general health, outside research settings. This document aims to promote safe, evidence-informed and clinically appropriate use and to clarify areas where further research is needed.
Authors
- Manuel Sánchez‐Prieto (ORCID: https://orcid.org/0000-0001-7366-0446)
- Camil Castelo‐Branco (ORCID: https://orcid.org/0000-0002-9860-8318)
- Santiago Palacios (ORCID: https://orcid.org/0000-0003-2229-1200)
- Nicolás Mendoza (ORCID: https://orcid.org/0000-0002-1653-2509)
- Francisca Molero
- Rafael Sánchez‐Borrego (ORCID: https://orcid.org/0000-0001-6583-7440)
- Pluvio Coronado
- Ana Rosa Jurado
- Luisa Esther Gutiérrez
- Eva Iglesias Bravo
Publication Details
- Journal
- Figshare
- Published
- 2026-11-19
- DOI
- https://doi.org/10.6084/m9.figshare.35068587
- Primary Topic
- Hormonal and reproductive studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00